Bnb Plus Corp. (BNBX) Stock Price & Analysis
Bnb Plus Corp. (BNBX) rose 0.00% to USD 0.09 as of July 25, 2026 at 07:43 UTC, according to Nexqual real-time market data.
BNBX last closed at USD 0.09; the session ranged USD 0.07–0.1 on volume of 125,983 shares. Market capitalization is $647,750, with a 52-week range of USD 0.07–7.15 (OQB). Source: Nexqual, July 25, 2026 at 07:43 UTC.
Key Statistics (as of July 25, 2026 at 07:43 UTC)
| Price | USD 0.09 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.09 |
| Open | USD 0.1 |
| Day Range | USD 0.07 – 0.1 |
| 52-Week Range | USD 0.07 – 7.15 |
| Volume | 125,983 shares |
| Market Cap | $647,750 |
| Exchange | OQB |
Technical Analysis (BNBX)
Nexqual's technical model rates BNBX "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 07:43 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 19.94 (oversold) |
| vs SMA50 | Below (USD 0.37) |
| MACD | -0.09 (negative) |
Analyst Ratings (BNBX)
Wall Street analysts rate BNBX "None", per Nexqual as of July 25, 2026 at 07:43 UTC.
| Consensus Rating | None |
|---|
Earnings (BNBX)
| Next Earnings Date | 2026-05-15 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-06-30 | USD -33.42 vs est -37.5 ▲ beat |
| 2025-03-31 | USD -230.89 vs est -45 ▼ miss |
| 2024-12-31 | USD -421.2 vs est -247.5 ▼ miss |
Source: Nexqual, July 25, 2026 at 07:43 UTC.
Financials & Fundamentals (BNBX)
| Total Revenue | $2.09M |
|---|---|
| Revenue Growth (YoY) | +34.30% |
| Gross Margin | +46.78% |
| Operating Margin | -636.41% |
| Profit Margin | +0.00% |
| ROE | -306.79% |
| Current Ratio | 1.82 |
| Total Cash | $949,091 |
| Total Debt | $0 |
| Free Cash Flow | $-19.03M |
Source: Nexqual, July 25, 2026 at 07:43 UTC.
Financial Health Score (BNBX)
Nexqual rates Bnb Plus Corp.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 07:43 UTC.
| Growth | Critical — Revenue -38% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $949K cash, no debt |
| Cash Flow | Weak — FCF negative: -$19M, burning cash |
| Efficiency | Critical — ROE -307%, ROA -152.1% |
Ownership (BNBX)
| Insider Ownership | +9.41% |
|---|---|
| Institutional Ownership | +7.33% |
| Shares Outstanding | 7.20M |
| Float | 7.10M |
| Short % of Float | +2.50% |
Source: Nexqual, July 25, 2026 at 07:43 UTC.
Leadership (BNBX)
Bnb Plus Corp. is led by Clay D. Shorrock Esq. (age 40), President & CEO, per Nexqual as of July 25, 2026 at 07:43 UTC.
| President & CEO | Clay D. Shorrock Esq. (age 40) |
|---|---|
| Chief Financial Officer | Beth M. Jantzen (age 49) |
| Director, Strategic Transition Advisor & Secretary | Judith Murrah (age 67) |
| Executive Director of Investor Relations & Corporate Communications | Sanjay M. Hurry |
Major Backers & Investors (BNBX)
Notable institutional backers of Bnb Plus Corp. include Intrinsic Edge Capital Management LLC, Galaxy Group Investments LLC, Galaxy Digital Inc., according to Nexqual as of July 25, 2026 at 07:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Intrinsic Edge Capital Management LLC | 4.03% |
| Galaxy Group Investments LLC | 2.62% |
| Galaxy Digital Inc. | 1.67% |
| Fidelity | 1.02% |
| Citadel | 0.86% |
| Two Sigma Securities, LLC | 0.4% |
| Xtx Topco Ltd | 0.19% |
| Sabby Management, LLC | 0.19% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.06% |
| Vanguard Group | 0.24% |
Source: Nexqual, July 25, 2026 at 07:43 UTC.
From Bnb Plus Corp.'s Latest SEC 10-K Filing (filed 2025-12-22)
Key Strengths & Strategy (as disclosed to the SEC)
- BNB Plus Corp. provides digital asset treasury services.
- The company offers real-time data tracking of treasury performance and market indicators.
- The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally.
- The company engages in the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and nucleic acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP, and LineaIVT, as well as the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GOVX | GeoVax Labs, Inc. | USD 0.73 | ▼ 21.9% |
| AEMD | Aethlon Medical, Inc. | USD 0.58 | ▼ 0.9% |
| NNVC | NanoViricides, Inc. | USD 1.48 | ▼ 2.63% |
| ADTX | Aditxt, Inc. | USD 0 | ▲ 33.33% |
| BMRA | Biomerica, Inc. | USD 1.59 | ▲ 0.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:43 UTC. This page is informational and not investment advice.